IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion

Area of Science:

• Immunology
• Molecular Biology
• Cancer Biology

Background:

• Glycosylation of immune receptors and ligands is crucial for immune signaling and surveillance.
• The precise mechanisms by which oncogenic signaling initiates glycosylation of coinhibitory molecules to promote immunosuppression are not fully understood.

Purpose of the Study:

• To elucidate the mechanism by which interleukin-6 (IL-6) signaling initiates the glycosylation of programmed death-ligand 1 (PD-L1).
• To investigate the therapeutic potential of targeting IL-6 and PD-L1 in combination with anti-T cell immunoglobulin mucin-3 (anti-Tim-3) therapy.

Main Methods:

• Investigated the phosphorylation of PD-L1 by IL-6-activated JAK1.
• Utilized STT3A, an N-glycosyltransferase, to catalyze PD-L1 glycosylation.
• Evaluated combination therapy of IL-6 antibody and anti-Tim-3 in animal models.
• Correlated IL-6 and PD-L1 expression in hepatocellular carcinoma patient tissues.

Main Results:

• IL-6-activated JAK1 phosphorylates PD-L1 at Tyr112, recruiting STT3A for glycosylation and stability.
• IL-6 antibody combined with anti-Tim-3 therapy demonstrated synergistic T cell killing in preclinical models.
• A positive correlation between IL-6 and PD-L1 expression was observed in hepatocellular carcinoma patients.

Conclusions:

• Identified a novel mechanism regulating PD-L1 glycosylation initiation through IL-6/JAK1 signaling.
• Suggests a marker-guided therapeutic strategy combining IL-6 blockade and anti-Tim-3 therapy for hepatocellular carcinoma.